Advertisement

Topics

Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test

20:36 EDT 22 Sep 2016 | SCRIP

Lundbeck’s 5-HT6 antagonist idalopirdine failed its first Phase III test, but as Axovant awaits data from its Phase III study...

      

Related Stories

 

Original Article: Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test

NEXT ARTICLE

More From BioPortfolio on "Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test"

Quick Search
Advertisement
 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...